Patents by Inventor Martin Quibell

Martin Quibell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6528275
    Abstract: The present invention relates to the field of compounds which are substrates or inhibitors of proteolytic enzymes and to apparatus and methods for identifying substrates or inhibitors for proteolytic enzymes. We have devised a combinatorial method for the rapid indentification of binding motifs which will greatly expedite the synthesis of inhibitors of a variety of proteolytic enzymes such as aspartyl proteases, serine proteases, metallo proteases and cysteinyl proteases.
    Type: Grant
    Filed: November 3, 1999
    Date of Patent: March 4, 2003
    Assignee: Peptide Therapeutics Limited
    Inventors: Martin Quibell, Tony Johnson, Terance Hart
  • Patent number: 6372885
    Abstract: Method for preparing a combinatorial chemistry library of compounds of the formula R1—C(═O)—NH—R2, wherein R1 and R2 are as defined in the specification, which comprises acylating a combinatorial chemistry intermediate of the formula 1A wherein Y1, Y2, X, n, R1 and R2 are as defined in the specification to produce a compound of the formula wherein Y1, R1, R2 and X are as defined in the specification, followed by acidolytic cleavage of the resin bound linker to release the compound of the formula R1—C(═O)—NH—R2.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: April 16, 2002
    Assignee: Peptide Therapeutics Limited
    Inventors: Tony Johnson, Martin Quibell
  • Patent number: 6034066
    Abstract: The invention provides compounds for use in the treatment of allergic diseases including juvenile asthma and eczema. The compounds can inhibit IgE mediated reaction to major environmental and occupational allergens and can also have a prophylactic effect against allergic disease by preventing allergic sensitization to environmental and occupational allergens when administered to at-risk individuals (e.g., those at genetic risk of asthma and those exposed to occupational allergens in the workplace). The compounds are also useful for inactivation or attenuation of the allergenicity of allergens in situ. The invention provides compounds and ligands per se, pharmaceutical compositions containing the compounds, processes for producing the compounds and pharmaceutical compositions, and methods for using the compounds and compositions in treatment or prophylaxis of IgE mediated allergic diseases and in inactivation or attenuation of allergens in situ.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: March 7, 2000
    Assignee: Peptide Therapeutics Limited
    Inventors: Tony Johnson, Terrance Hart, Peter Laing, Farouk Shakib, Martin Quibell